DLL3
Assets acting on this target.
- Class
- CAR-T
By indication
Related mechanisms
DLL3 drugs compared
3 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| SHR-4849 | Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 2 | Phase 1 in Advanced Solid Tumors |
| DJI136 | Novartis | cell therapy (CAR-T) | Phase 1/2 | Phase 1/2 in Small Cell Lung Cancer |
| 225Ac-ETN029 | Novartis | radioligand therapy (actinium-225) | Stage not recorded | Not recorded |